Intelligent Livingの空売り状況は、投資家がIntelligent Livingの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Intelligent Living (NASDAQ:ILAG) 株価情報, 空売り情報

Intelligent Living

Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.

Intelligent Living Application Group Inc. - Ordinary Shares

Intelligent Living Application Group Inc

At Applied Digital's Ellendale, North Dakota campus, BASX is deploying bespoke free cooling chillers — optimized for cold-climate operation, reducing power demand, and requiring zero water consumption
REDMOND, Ore., June 30, 2025 /PRNewswire/ --&nbsp;BASX, a leader in advanced cooling and custom solutions for data centers and mission-critical environments, and a wholly owned subsidiary of AAON, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>), a leading provider of high-performance, energy-efficient HVAC solutions, today announced a partnership with Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) ("Applied Digital"). Applied Digital, a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (HPC) applications.
As part of the collaboration, BASX designed and manufactured a customized free cooling chiller system for Applied Digital's AI factory in Ellendale, North Dakota, known as Polaris Forge 1. The system is purpose-built to meet the performance demands of AI infrastructure in a cold climate, while maximizing energy efficiency and sustainability.

News

AAON

APLD

AAON's BASX Partners With Applied Digital For Next-Gen High-Performance Computing Applications

Leerink Partners analyst Jonathan Chang maintains Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) with a Outperform and raises the price target from $73 to $75.

Price Target

Analyst Ratings

ZLAB

Leerink Partners Maintains Outperform on Zai Lab, Raises Price Target to $75

General

AAPL

Reuters Cites Court Ruling Saying Apple Must Face US Antitrust Lawsuit Accusing It Of Monopolizing Smartphone Market

<a href="https://asia.nikkei.com/Business/Automobiles/Honda-delays-cuts-target-for-Japan-fuel-cell-production-plans">https://asia.nikkei.com/Business/Automobiles/Honda-delays-cuts-target-for-Japan-fuel-cell-production-plans</a>

'Honda delays, cuts target for Japan fuel cell production plans'- Nikkei Asia

SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares are up 7% on Monday, adding to strong gains over the past three months. As the second quarter comes to a close, here&#8217;s a look at key highlights from the period.
What Happened: SoundHound shares are on pace to close out the second quarter up approximately 30%. Recent analyst coverage suggest the stock may have more room to run.
Piper Sandler initiated coverage in late May with a price target of $12 and Wedbush and HC Wainwright maintained Outperform and Buy ratings last month with price targets of $15 and $18, respectively.
SoundHound has a strong momentum score of 90.62, according to <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjliKyC25mOAxVaD1kFHc8zL8IQFnoECCMQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>. For more trend information sign up for Pro or check out Benzinga&#8217;s rankings tools on <a href="https://www.benzinga.com/quote/SOUN">SoundHound AI Stock Price, Quotes and Forecasts</a>.
SoundHound reported first-quarter results last month, showing 151% growth despite narrowly missing revenue estimates.
The company guided for full-year revenue of $157 million to $177 million, versus analyst estimates of $166.17 million.
&#8220;SoundHound continues to extend its reach and create new possibilities for real world AI applications. The release of our complete AI agent platform delivers full, voice-enabled Agentic AI for customers across all industries,&#8221; the company said in its first-quarter earnings release.
SoundHound is due to report second-quarter results in early August, although a date has not yet been set by the company. Analysts expect a loss of 9 cents per share on quarterly revenue of $32.88 million. The company had consistently beat estimates for several quarters before missing revenue expectations in its most recent report.
Related Link: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46176358/cava-stock-has-fallen-over-the-past-three-months-whats-going-on">Cava Stock Has Fallen Over The Past Three Months: What&#8217;s Going On?</a>
SOUN Price Action: At the time of writing, SoundHound stock is trading 8.85% higher at $10.70, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjliKyC25mOAxVaD1kFHc8zL8IQFnoECCMQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock

Movers

SOUN

SoundHound Stock Has Risen Over The Past Three Months: What's Going On?

Telsey Advisory Group analyst Joseph Feldman maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Outperform and maintains $455 price target.

Telsey Advisory Group Maintains Outperform on Home Depot, Maintains $455 Price Target

WIIM

METC

Ramaco Resources shares are trading higher after the company announced it will release updated information regarding its Brook mine rare earth and critical minerals project on July 1st.

INDV

Indivior shares are trading higher after the company was added to the Russell 2000 index. Additionally, Craig-Hallum raised its price target on the stock from $15 to $22.

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>), highlighting the company&#8217;s &#8220;rebirth&#8221; following the in-licensing of telitacicept.
On Thursday, the company announced a strategic licensing agreement and a major capital raise to support its <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46120176/why-this-biotech-stock-just-doubled-in-a-single-day" rel="noreferrer noopener">push into autoimmune therapies</a>.
Vor Bio signed an exclusive global licensing deal with RemeGen Co., Ltd., giving it rights outside Greater China to develop and commercialize telitacicept, a dual-action fusion protein already approved in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46108474/puretech-founded-entity-vor-bio-announces-exclusive-global-license-agreement-with-remegen-for-late" rel="noreferrer noopener">China for multiple autoimmune disorders</a>.
Also Read: <a href="https://www.benzinga.com//node/46120176">Why This Biotech Stock Just Doubled In A Single Day</a>
Under the agreement, Vor will pay $125 million upfront, $45 million in cash, $80 million in stock warrants, and potential milestone payments exceeding $4 billion and tiered royalties.
The company also announced that Jean-Paul Kress has stepped in as CEO and Chairman, replacing Dr. Robert Ang, who will stay on as a strategic advisor through October.
Commenting on the development, HC Wainwright stated, &#8220;Overall, we are encouraged by the quick resurrection of the company by the board and the management as this transaction brings a de-risked asset that could be commercialized in the US starting mid-2028.&#8221;
Analyst Swayampakula Ramakanth upgraded Vor Biopharma from Neutral to Buy on Monday with a <a target="_blank" href="https://www.benzinga.com/quote/VOR/analyst-ratings" rel="noreferrer noopener">price forecast of $3</a>.
Ramakanth highlights the significant market opportunity for telitacicept in generalized myasthenia gravis (gMG). Based on a 2018 survey of Medicare data, an estimated 82,700 people in the U.S. had gMG in 2021, with approximately 75% receiving treatment.
The analyst projects that if telitacicept is priced at $225,000 per patient yearly and captures 15% of the U.S. market, peak annual sales could reach $1.8 billion.
Furthermore, the analyst says, should the drug successfully launch in the EU and Japan, with commercial partners managing sales outside the U.S. and achieving a 10% market share, it could generate an additional $2.7 billion in combined sales and royalties.
While RemeGen is conducting a Phase 3 trial of telitacicept for lupus (SLE) in the U.S. and EU, the analyst notes that Vor Biopharma currently lacks a defined strategy for marketing the drug for SLE. Consequently, any potential sales from this indication are not factored into Vor&#8217;s current projections.
Price Action: VOR stock is up 49.1% at $1.58 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46165307/us-credit-rating-would-fall-if-trumps-big-beautiful-bill-is-approved-says-thomas-massie-heres-what-it-means-for-americans" target="_blank" rel="noreferrer noopener">US Credit Rating Would Fall If Trump&#8217;s Big Beautiful Bill Is Approved, Says Thomas Massie: Here&#8217;s What It Means For Americans</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Upgrades

Health Care

Trading Ideas

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

TROX

Tronox Holdings shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and cut its price target from $7 to $3.

Leonardo DRS shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a price target of $49.

Wall Street veteran and Fundstrat co-founder Tom Lee is set to bring Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) into the spotlight, with plans to position BitMine Immersion Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) as the &#8216;<a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">MicroStrategy of Ethereum.</a>&#8216;
What Happened: In an CNBC Squawk <a href="https://www.cnbc.com/video/2025/06/30/fundstrats-tom-lee-on-being-named-chairman-of-bitmine-immersion-technologies.html">interview</a> on June 30, Lee announced his new role as chairman of BitMine, a small-cap Bitcoin mining firm valued at $26 million. 
Under his leadership, BitMine will pivot from being purely a miner to an Ethereum-focused treasury company, adopting ETH as its primary reserve asset.
To kick off the transition, BitMine has announced a $250 million private placement, which will be used to accumulate Ether while maintaining its existing Bitcoin mining operations.
Lee stressed Ethereum's vital role in powering the stablecoin ecosystem, calling stablecoins the &#8220;ChatGPT of crypto&#8221; due to their rapid and widespread adoption. 
By holding ETH, Lee believes BitMine can help support and benefit from the infrastructure underpinning stablecoins.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46175268/ethereum-traders-target-4000-in-summer-whats-fueling-the-optimism">Ethereum Traders Target $4,000 In Summer: What&#8217;s Fueling The Optimism?</a>
Why It Matters: BitMine will begin tracking ETH-per-share as its principal performance metric, emulating how Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) uses BTC-per-share to communicate shareholder value. 
The firm plans to grow this figure via Ethereum price appreciation, reinvested cash flows, and strategic capital market activities.
This marks a shift in corporate treasury strategies, with a growing number of firms now exploring Ether and Solana-based reserves. Companies like SharpLink Gaming and DeFi Development have already started integrating ETH into their treasuries.
Just last week, <a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">Lee praised MicroStrategy's model</a>, noting its ability to outperform Bitcoin through clever capital deployment, including the issuance of convertible debt at near-zero interest rates to acquire more BTC. 
He believes BitMine can replicate that success, but with Ethereum at its core.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46139888/michael-saylor-says-bitcoin-treasury-companies-can-unlock-even-more-growth-heres-how">Michael Saylor Says Bitcoin Treasury Companies Can Unlock Even More Growth: Here&#8217;s How</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

BMNR

MSTR

Inside Tom Lee's Plan To Build 'MicroStrategy Of Ethereum' At BitMine

Last week, CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.
The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned, with an opportunity for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46048778/cormedix-inc-announces-customer-implementation" rel="noreferrer noopener">even further expansion</a>.
As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year.
The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46059139/cormedix-stock-hits-new-52-week-high-on-updated-guidance-the-details" rel="noreferrer noopener">CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details</a>
DefenCath is a catheter <a target="_blank" href="https://www.defencath.com/" rel="noreferrer noopener">lock</a> solution to reduce the risk of catheter-related bloodstream infections (CRBSIs) in adults with kidney failure undergoing chronic hemodialysis via a central venous catheter. The FDA approved the product in 2023.
HC Wainwright initiated coverage on CorMedix, citing &#8220;good things are worth the wait&#8230;&#8221;
Analyst Brandon Folkes wrote, &#8220;We believe DefenCath&#8217;s strong launch to date is indicative of good results these operators are seeing in practice, and in our view, this real world experience, along with the more formal real-world study DefenCath in undertaking is likely to support a more durable DefenCath long term revenue stream in CRBSIs than is currently reflected.&#8221;
HC Wainwright initiated with a Buy rating, <a target="_blank" href="https://www.benzinga.com/quote/CRMD/analyst-ratings" rel="noreferrer noopener">with a price forecast of $20</a>.
The company is in the initial t-year of the Transitional Drug Add-on Payment Adjustment (TDAPA) period and will enjoy a further three years post this initial reimbursement period, albeit at a lower level. The analyst sees potential for further outperformance in CorMedix stock.
Folkes added, &#8220;As we see longer-term revenue expectations come closer together and remove the uncertainty and wide variation, we believe CRMD investors could be further rewarded.&#8221;
On Friday, CorMedix priced its previously announced underwritten public offering of 6.6 million, with gross proceeds expected to be<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46136775/cormedix-inc-announces-pricing-of-public-offering-of-common-stock" rel="noreferrer noopener"> approximately $85 million</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>
Photo: MacroEcon via Shutterstock.

CRMD

CorMedix Analyst Says Investors Could Be Further Rewarded

<a href="https://truthsocial.com/@realDonaldTrump/114773696636727417">https://truthsocial.com/@realDonaldTrump/114773696636727417</a>

President Trump Posts On Truth Social "I apologize for the long wait on the Faith Leaders Conference Call. AT&T ought to get its act together. Please pass along the word to the tens of thousands of people who are there. We may have to reschedule the call, but we'll use another carrier the next time. AT&T obviously doesn't know what they're doing!"

New Fortress Energy shares are trading higher after the company announced it signed an LNG supply contract extension with Puerto Rico's government.

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/topic/nvidia" target="_blank" rel="noreferrer noopener">stock surged 44%</a> in the previous three months while the PHLX Semiconductor Sector Index (SOX), which Nvidia is part of, gained 29.41% during the period.
The stock is currently trading near its 52-week high of $158.71.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46149318/microsofts-next-gen-ai-chip-still-lags-nvidias-blackwell-postpones-launch" target="_blank" rel="noreferrer noopener">Microsoft&#8217;s Next-Gen AI Chip Still Lags Nvidia&#8217;s Blackwell, Postpones Launch</a>
In May, Nvidia reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" rel="noreferrer noopener">first-quarter revenue</a> growth of 69% to $44.1 billion, topping the Street consensus estimate of $43.2 billion. The revenue increased by 12% sequentially.
Adjusted EPS of 96 cents topped the analyst consensus estimate of 88 cents.
Nvidia faced an export ban on H20 products to China on April 9. The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations.&nbsp;
Nvidia forecasted second-quarter revenue of $45 billion, plus or minus 2%, versus&nbsp;estimates of $45.78 billion. The company noted its outlook reflects a loss of approximately $8 billion in H20 revenue due to the export control limitations.
Multiple Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/NVDA/analyst-ratings" rel="noreferrer noopener">raised their price targets</a> on the company after the results.
Nvidia has a consensus price target of&nbsp;$178.46&nbsp;based on the ratings of&nbsp;38&nbsp;analysts. The high is&nbsp;$250,&nbsp;issued by&nbsp;Loop Capital&nbsp;on&nbsp;June 25, 2025.&nbsp;
Nvidia made at least one acquisition during the quarter. As of June 27, Nvidia acquired&nbsp;Canadian AI startup, CentML, <a href="https://www.benzinga.com/m-a/25/06/46149909/nvidia-ai-acquisition" target="_blank" rel="noreferrer noopener">for undisclosed terms</a>.&nbsp;
CentML specializes in&nbsp;optimizing AI, offering innovative solutions that significantly enhance efficiency and performance.
The chip designer tapped CentML CEO Gennady Pekhimenko as a senior director for AI software at Nvidia.
CentML plans to optimize both model training and inference by running models after they&#8217;ve been trained.
Graphics processing units (GPUs) are also heavily used in inference today, and Pekhimenko noted them as a potential avenue of growth for the company.
Wedbush&#8217;s Dan Ives&nbsp;indicated&nbsp;that Nvidia is on a path to a <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45668727/nvidia-stock-is-surging-thursday-whats-fueling-the-move" target="_blank" rel="noreferrer noopener">$4 trillion market cap</a>, eventually reaching $5 trillion, backed by increasing AI spending.&nbsp;
Deepwater&#8217;s Gene Munster&nbsp;highlighted Nvidia&#8217;s core business&#8217;s impressive growth when excluding the impacts of the China chip restrictions.
Bank of America analyst&nbsp;Vivek Arya&nbsp;estimated that Nvidia&nbsp;holds 80%-85%&nbsp;of the total market for AI data center chips. The Blackwell platform prompted Arya to raise his earnings forecast for the calendar year 2027 to $7.23 per share, which is up 12%. He had projected long-term earnings power of $10 per share, driven by the company's AI hardware moat.
NVDA Price Action:&nbsp;NVDA stock is down slightly at $157.65 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46125295/google-future-wall-street-ai-hype-meets-skepticism" target="_blank" rel="noreferrer noopener">Google Future Divides Wall Street As AI Hype Meets Skepticism</a></li>
</ul>
Photo: Shutterstock

Tech

NVDA

What Is Going On With Nvidia Stock?

<a href="https://truthsocial.com/@realDonaldTrump/114773668772907430">https://truthsocial.com/@realDonaldTrump/114773668772907430</a>

President Trump Posts On Truth Social "I'm doing a major Conference Call with Faith Leaders from all over the Country, and AT&T is totally unable to make their equipment work properly. This is the second time it's happened. If the Boss of AT&T, whoever that may be, could get involved — It would be good. There are tens of thousands of people on the line!"

<a href="https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions?embedded-checkout=true</a>

'EU Wants The US To Commit To Lower Rates On Key Sectors Such As Pharmaceuticals, Alcohol, Semiconductors And Commercial Aircraft; EU Is Also Pushing The US For Quotas And Exemptions To Effectively Lower Washington's 25% Tariff On Automobiles And Car Parts; EU Is Also Pushing The US For Quotas And Exemptions To Effectively Lower Washington's 50% Tariff On Steel And Aluminum'- Bloomberg

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) on Monday with a Buy rating and a <a href="https://www.benzinga.com/quote/AARD/analyst-ratings">price forecast of $40</a>.
In February, Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) priced an initial public offering of 5.9 million at $16 per share, with approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43682266/aardvark-therapeutics-announces-pricing-of-initial-public-offering" rel="noreferrer noopener">$94.2 million in gross proceeds</a>.
Aardvark is a&nbsp;clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics to activate innate homeostatic pathways for metabolic diseases.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/46175777/fda-flags-major-safety-concerns-for-argenxs-nerve-disorder-drug-stock-falls">FDA Flags Major Safety Concerns For Argenx&#8217;s Nerve Disorder Drug, Stock Falls</a>
Aardvark&#8217;s lead product candidate, ARD-101, targets Bitter Taste Receptors (TAS2Rs) expressed in the gut lumen, inducing secretion of endogenous signaling molecules, including the satiety hormone cholecystokinin (CCK), which in turn activates gut-brain signals to suppress the sensation of hunger.
Unlike many existing obesity treatments that act systemically and can cause significant gastrointestinal (GI) side effects like nausea, vomiting, and diarrhea, ARD-101 targets specific receptors in the gut.
ARD-101 aims to reduce hunger and facilitate weight loss without the typical systemic side effects. Importantly, its gut-restricted nature means minimal systemic exposure, potentially minimizing off-target effects and preserving lean muscle mass, which is a common concern with some weight loss methods.
The drug candidate has entered Phase 3 development for hyperphagia associated with Prader-Willi Syndrome. Data readout is expected in early 2026. The company holds Orphan Drug Designation for ARD-101 in PWS.
Aardvark believes that its existing cash, cash equivalents, and short-term investments, together with the proceeds from the IPO, will be sufficient to fund projected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45420113/aardvark-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-highlight" rel="noreferrer noopener">operations into 2027</a>.
Analyst Raghuram Selvaraju noted that there is only one branded medication currently approved in PWS, namely, Vykat XR (diazoxide choline extended-release), launched in April 2025, which has a list price of over $466K in the U.S. 
Accordingly, the analyst feels that the pricing and competitive landscape dynamics appear favorable, even if the target patient population is small (roughly 20K patients in the U.S.)
FDA approved Soleno Therapeutics, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44512290/soleno-therapeutics-secures-fda-approval-for-its-first-commercial-drug-for-rare-genetic-disorder" rel="noreferrer noopener">age and older with PWS</a>.
Selvaraju believes that &#8220;ARD-101 could achieve robust market share even if it does not have comparable or superior efficacy to existing approved agents, if it proves the hypothesis that the mechanism of action ought to yield significantly better safety and tolerability (particularly with respect to GI side effects).&#8221; 
Beyond Prader-Willi Syndrome, ARD-101 is also being evaluated in the Phase 2 HONOR trial for patients with hypothalamic obesity (HO). The analyst views ARD-101 as an &#8220;intriguing treatment alternative for HO patients because of its oral route of administration and benign safety profile.&#8221; Hypothalamic obesity is a challenging condition with limited approved treatments.
Price Action: AARD stock was up 4.11% at $13.94 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46167825/bitmine-immersion-technologies-stock-is-soaring-monday-whats-going-on" target="_blank" rel="noreferrer noopener">BitMine Immersion Technologies Stock Is Soaring Monday: What&#8217;s Going On?</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Initiation

AARD

SLNO

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

Investors with a lot of money to spend have taken a bullish stance on Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HWM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Howmet Aerospace.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $196,200, and 5 are calls, for a total amount of $269,633.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $210.0 for Howmet Aerospace over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Howmet Aerospace's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Howmet Aerospace's whale activity within a strike price range from $155.0 to $210.0 in the last 30 days. 
<h3>Howmet Aerospace Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751306490_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HWM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.1</td>
<td>$24.7</td>
<td>$25.1</td>
<td>$200.00</td>
<td>$67.7K</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$6.4</td>
<td>$6.2</td>
<td>$6.4</td>
<td>$210.00</td>
<td>$64.0K</td>
<td align="right">806</td>
<td align="right">206</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.7</td>
<td>$27.6</td>
<td>$27.7</td>
<td>$175.00</td>
<td>$58.1K</td>
<td align="right">131</td>
<td align="right">21</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$7.3</td>
<td>$4.2</td>
<td>$5.8</td>
<td>$210.00</td>
<td>$58.0K</td>
<td align="right">806</td>
<td align="right">0</td>
</tr>
<tr>
<td>HWM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$5.7</td>
<td>$5.2</td>
<td>$5.15</td>
<td>$160.00</td>
<td>$51.5K</td>
<td align="right">444</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Howmet Aerospace</h3>
Howmet Aerospace Inc produces products that are majorly used in aerospace, commercial transportation, and industrial and other markets. The company seeks to provide its customers with solutions by offering differentiated products such as airfoils with cooling and coatings for extreme temperature applications, specially designed fasteners for lightweight composite airframe construction, reduced assembly costs, lightning strike protection, and lightweight aluminum commercial wheels. It has four reportable segments namely, Engine Products, Fastening Systems, Engineered Structures, and Forged Wheels.
<h3>Where Is Howmet Aerospace Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,109,803, with HWM's price down by 0.0%, positioned at $184.9.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>What The Experts Say On Howmet Aerospace</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $196.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Howmet Aerospace, maintaining a target price of $200. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Howmet Aerospace with a target price of $192. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Howmet Aerospace, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Comments

Intelligent Living

空売り

Intelligent Living (NASDAQ:ILAG) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル